Abstract: Diabetic nephropathy is one of the major microvascular complications of diabetes mellitus which ultimately gives rise to cardiovascular diseases. Prolonged hyperglycaemia and chronic renal inflammation are the two key players in the development and progression of diabetic nephropathy. Nuclear factor kB (NF-kB)-mediated inflammatory cascade is a strong contributor to the renovascular inflammation in diabetic nephropathy. Here, we studied the effects of piceatannol, a potent NF-kB inhibitor, on various oxidative stress markers and NF-kB dependent diabetic renoinflammatory cascades in rat induced by alloxan (ALX). Experimental diabetes was induced in male Wistar rats by a single intraperitoneal dose, 150 mg/kg body-weight (b.w.) of ALX. Diabetic rats were treated with Piceatannol (PCTNL) at a dose of 30 and 50 mg/kg b.w. After 14 days of oral treatment, PCTNL significantly restored blood sugar level, glomerular filtration rate, serum markers and plasma lipids. PCTNL administration also reversed the declined activity of cellular antioxidant machineries namely superoxide dismutase and glutathione and the elevated levels of malondialdehyde and nitric oxide. Moreover, piceatannol-treated groups showed marked inhibition of renal pro-inflammatory cytokines and NF-kB p65/p50 binding to DNA. Renal histopathological investigations also supported its ameliorative effects against diabetic kidney damage. Importantly, effects were more prominent at a dose of 50 mg/kg, and in terms of bodyweight gain, PCTNL failed to effect significantly. However, overall findings clearly demonstrated that PCTNL provides remarkable renoprotection in diabetes by abrogating oxidative stress and NF-kB activation -and might be helpful in early stage of diabetic nephropathy.
Diabetes mellitus (DM) is a global health crisis today that mostly affects people from developing countries. In 2012, 3.7 million deaths occurred from DM and 2.2 million of these deaths occurred from its associated complications. The estimated global diabetic population was 422 million in 2014 and is projected to increase to 439 million by 2030, which is equal to 7.7% of total adult population [1] . DM is a non-communicable disease characterized by impaired glucose tolerance which ultimately results in microvascular complications, mainly precipitated as neuropathy, retinopathy and nephropathy [2, 3] . Diabetes-associated cardiovascular complications are the principal causes of most deaths occurring in DM, which is partly originated from damage to the renal microvasculature [4] . Diabetic microvasculopathy of kidney or diabetic nephropathy is the single most important cause of end-stage renal disease and contributes to 40% of new cases worldwide [5] .
Alloxan (ALX)-induced diabetes model in rodents is very often used to investigate potential drug candidates for DM and its related complications. By producing selective beta cell toxicity, ALX exerts its diabetogenic action when intraperitoneally administered to rodents [6, 7] . Chronic hyperglycaemic condition thereby produced due to impaired secretion of insulin, increases oxidative stress and activates renal inflammatory cascades [8] . Nuclear factor kB (NF-kB) mediated inflammatory pathway is reported to play a pivotal role in the pathogenesis of diabetic renal vasculopathy [9] .
Resveratrol, a naturally occurring trans-3,4 0 ,5-trihydroxystilbene, has been reported to possess beneficial effects against many cancers, atherosclerosis, oxidative stress and inflammatory conditions. A less studied hydroxylated analogue of resveratrol, piceatannol (PCTNL) or 3,3 0 ,4,5 0 -trans-tetrahydroxystilbene ( fig. 1 ) is found in nature, mainly in plants such as Euphorbia lagascae, black grapes, white tea, passion fruit, rhubarb, Asian legume, Japanese knotweed etc. This stilbene has been found to have antiproliferative [10] , antiangiogenic [11] , pro-apoptotic [12] , antimetastatic [13, 14] , antipromotion and antiprogression [15] activities against a number of cancer cell lines. Recently, antileukaemic potential of PCTNL has been reported against childhood acute lymphoblastic leukaemia [16] . Further studies suggested that this resveratrol analogue possesses potent Syk and STAT3 inhibitory properties [17, 18] . Moreover, it has been reported that PCTNL effectively inhibits bacterial lipopolysaccharide-induced inducible nitric oxide synthase in macrophages [19] . Anti-inflammatory property of PCTNL has been attributed to its ability to suppress activation of NF-kB [17, 20] , through inhibition of IkBa and phosphorylation of p65 subunit [17, 19] . In this study, we investigated effects of PCTNL on NF-kB-mediated renal inflammatory pathway and oxidative stress in ALX-induced diabetic Wistar rat. Animals were isolated individually on the 14th day of the treatment, into metabolic cages to measure urine output. On completion of the study, the fasting blood glucose level and body-weight of each animal were recorded. Overnight-fasted animals were anaesthetized with ether and sacrificed by cervical dislocation after collection of blood. Collected blood samples were kept undisturbed at room temperature for 15 min. Then, they were centrifuged at 2000 9 g for 10 min. in a refrigerated centrifuge (Heraeus Fresco 21; Thermo Scientific, USA) to remove the clots. The resultant serum was separated and stored immediately at À80°C. Kidneys were isolated, separated from extra tissues and washed with ice-cold solution of 0.90% w/v sodium chloride. A part of the kidneys was processed for NF-kB binding assay. Similarly, a part of each kidney was stored in 10% v/v neutral-buffered formalin for histopathology. The rest of the kidneys were minced and homogenized in ice-cold 0.1 M phosphate buffer solution (pH 7.4). The tissue homogenates were centrifuged at 12000 9 g using a refrigerated microcentrifuge (Heraeus Fresco 21; Thermo Scientific, USA) at 4°C, for 30 min. The supernatants were collected, made aliquots and then, stored at À80°C.
Assessment of renal function and biochemical parameters. Serum and urine creatinine levels were estimated by using a semi-auto-analyser (IDEXX Vet Test Analyzer, 8008), and creatinine clearance (CrCl) was computed from the formula CrCl = [urine creatinine (lmol/ L) 9 volume of urine (mL/min)/serum creatinine (lmol/L)]. Similarly, serum albumin, blood urea nitrogen (BUN), aspartate transaminase (AST), alanine transaminase (ALT), triglycerides (TRIGs) and total cholesterol (TCHOL) levels were estimated to evaluate the effects of PCTNL on serum biochemical parameters.
Glycated haemoglobin (HbA 1C ) level is considered as gold standard index of glycaemic control in clinical practice to treat DM. Hence, we measured HbA 1C level of experimental groups using a colorimetric method described by Nayak et al. [25] .
Assessment of renal oxidative and nitrosative stress. Malondialdehyde (MDA) contents, as index of lipid peroxidation, in renal tissue were measured by the method described by Okhawa et al. [26] . Super oxide dismutase concentrations in the kidney samples of experimental groups were determined by a commercially available assay kit (Cat. no. 19160; Sigma-Aldrich). Non-enzymatic antioxidant GSH activity in the tissue homogenates was assayed by Ellman's reagent [27] . Total protein contents in the kidney tissues were estimated by Lowry's method [28] . The Griess reagent-based colorimetric method was used to determine the renal tissue nitric oxide (NO) level.
Assessment of renal pro-inflammatory cytokines. Estimation of renal tissue pro-inflammatory cytokines level was made by ELISA. Commercially available ELISA kits were purchased from Elabscience Biotechnology, Wuhan, China (TNF-a, cat. no. E-EL-R0019; IL-1b, cat. no. E-EL-R0012; and IL-6, cat. no. E-EL-R0015). The assays were carried out following individual protocols provided with the kits.
Assessment of renal NF-kB p50/p65 binding. The renal NF-kB inhibitory property of PCTNL was ascertained by measuring the extent of NF-kB p50/p65 binding to DNA in renal tissues. Commercially available NF-kB p50/p65 binding assay kit was purchased from Merck (Darmstadt, Germany; EZ-TFA NF-kB p50/ p65 colorimetric, assay kit, Code No-70-510). The estimation was carried out on nuclear extract of kidney tissue by following the manufacturer's instructions. At the end of the experiment, OD was measured at 450 nm using a microplate reader and expressed per milligram of tissue.
Histopathological assessment. Eight days after the rats were sacrificed, kidneys were removed from formalin and subjected to series of dehydration and cleaning with acetone and xylene, respectively. Then, the dehydrated kidneys were impregnated with paraffin, and 5-lm-thin sections were taken in a rotary microtome (HM 325; Thermo Scientific USA). The sections were stained with eosin and haematoxylin (H-E). Stained sections were mounted on slides and examined by a pathologist in the Department of Pathology, Gauhati Medical College & Hospital. Statistical analysis. One-way ANOVA (analysis of variance) was carried out using GraphPad Prism software followed by Tukey's multiple comparison test. Values were expressed in mean AE S.E.M. (where n = 6) and considered as statistically significant when p < 0.05.
Results
Effects of PCTNL on body-weight and blood glucose level. Diabetic rats showed a significant loss in body-weight in comparison with non-diabetic control rats receiving 0.5% w/v of CMC. PCTNL treatment failed to achieve significant bodyweight gain in the treated diabetic groups. Similarly, the diabetic rats exhibited marked hyperglycaemia recorded at the end of the treatment. PCTNL administration, however, dosedependently lowered the blood sugar levels (table 1) .
Effects of PCTNL on GFR and serum markers. The diabetic group exhibited marked reduction in Crcl, which in turn showed reduced glomerular filtration rate (GFR). Treatment with PCTNL at a dose of 30 and 50 mg/kg b.w, significantly (p < 0.05) improved Crcl. Serum AST, ALT and BUN were markedly elevated in diabetic rats, whereas a decrease in serum albumin contents was recorded. At the dose of 50 mg/kg b.w., PCTNL significantly reversed these changes. With respect to plasma lipid contents, PCTNL-supplemented groups exhibited low plasma TRIGs and TCHOL levels compared to the diabetic group (table 1) . HbA 1c was measured as another useful marker of glycaemic control. Untreated diabetic group showed remarkably higher level of HbA 1c when compared with the normal rats. In PCTNL-treated rats, HbA 1c levels were significantly (p < 0.05) low in comparison with diabetic rats receiving no treatment (table 1) .
Effects of PCTNL on oxidative stress and renal NO level. Diabetic rats exhibited a sharp increase in tissue MDA level in comparison with control animals. PCTNL at higher dose showed significant lipid peroxidation lowering effect, while a lesser dose failed to produce such effect. Renal superoxide dismutase (SOD) and GSH of the diabetic untreated group showed a significant (p < 0.05) drop in their activity. PCTNL treatment (at a dose of 30 and 50 mg/kg b.w.) significantly (p < 0.05) augmented the activity of these antioxidant machineries. Noticeably, PCTNL administration, only at 50 mg/kg b.w., significantly abolished the renal tissue nitrosative stress triggered indirectly by ALX (table 2) .
Effects of PCTNL on renal inflammation. Effects of PCTNL on renal pro-inflammatory cytokines are shown in fig. 2A -C. Renal tissues of diabetic rats receiving no treatment showed observably higher levels of IL-1b, IL-6 and TNF-a when compared with non-diabetic control rats. PCTNL only at a dose of 50 mg/kg b.w significantly (p < 0.05) suppressed all these pro-inflammatory cytokines, whereas the PCTNL-administered group at a dose of 30 mg/ kg b.w. showed no significant downturn of IL-1b and IL-6.
Effects of PCTNL on NF-kB p50/p65 binding to DNA. Non-diabetic kidney samples showed a very low level of NFkB p50/p65 binding to DNA. In contrast, renal tissues of diabetic untreated rats exhibited a massive increase in NF-kB p50/p65 binding to DNA. We observed a dose-dependent inhibition of renal NF-kB activation and binding in the groups supplemented with PCTNL for 14 days. Results are depicted in fig. 3 . glomerulopathy with severe damage to the renal corpuscular architectures with capsular space reduction (black arrows), glomerular sclerosis (red arrows), damage to the glomerular endothelial cells, tubular necrosis (green arrows) and tubular basement membrane thickening (brown arrows). Figure 4D displays a kidney section with preserved renal architecture of a rat receiving PCTNL alone. Figure 4E explains a diabetic kidney section receiving 30 mg/kg b.w. PCTNL treatment, with major improvements in corpuscular structures (red arrows), capsular spaces (black arrows) and with mild healing of necrotized tubules (green arrows). Figure 4F describes a renal photomicrograph of diabetic kidney on 50 mg/kg b.w. PCTNL treatment, showing almost preserved glomerular appearance with no sclerotic debris (red arrows), healing of tubular structures (green arrows) and normal capsular spaces (black arrows), comparable to normal renal microscopy.
Discussion
Diabetic nephropathy shares the major part of deaths occurring in DM, especially in type-2 [29] . Studies revealed that progression of the disease is multi-factorial and involves complex biochemical, metabolic and inflammatory processes [30] . Altered glucose tolerance results in a hyperglycaemic state, which in turn exerts oxidative stress. Further investigations have made it more evident that chronic renal inflammation is also equally responsible for disease progression in diabetic nephropathy [31, 32] . It has been reported that renal inflammation in diabetes is NF-kB linked. An increase in its nuclear translocation has also been reported in human DN [33, 34] . Many small molecules with NF-kB inhibitory property have shown to produce beneficial effects on inflammatory disease conditions [35] . This motivates us to evaluate the effects of PCTNL, reported to have potent NF-kB inhibitory action [17, 36] on ALX-induced diabetic nephropathy in male wistar rats. Typically, ALX produces type I diabetes, selectively causing free radical mediated b-cell toxicity [37] . In the present study, the experimental diabetic group receiving only ALX showed remarkably elevated blood sugar level, high blood urea nitrogen, reduced GFR and marked depletion of serum albumin levels. These characteristics typically reflect glomerular injury and renal dysfunction [4] . Our ns* = non-significant versus diabetic control. results showed that PCTNL during 14-days treatment significantly reverted the poor glycaemic control in the treated diabetic rats. Further, it significantly normalized elevated serum markers of oxidative cell damage, especially at the dose of 50 mg/kg b.w. These findings indicate nephroprotective action of PCTNL. However, PCTNL failed to achieve observable body-weight gain in the treated diabetic rats at any of the doses. Defective insulin secretion and poor glucose homeostasis lead to abnormal lipid and lipoprotein metabolism, precipitating a hyperlipidaemic state. These free lipids in the form of TRIGs and TCHOL accumulate in various body parts mainly affecting veins and arteries. The coronary arteries are more prone to such attacks [38, 39] . Our findings support the above evidences that the untreated diabetic rats exhibited a marked elevation of serum TRIGs and TCHOL when compared with non-diabetic rats. PCTNL supplementation showed a significant fall in the concentration of these serum lipids.
There is a linear corelation between glycated haemoglobin (HbA 1c ) and the progression of renal microvascular complications. Diabetic patients with renal insufficiency showed a significantly higher HbA 1c level. HbA 1c is formed when glucose non-enzymatically reacts with haemoglobin (Hb) of red blood cells (RBCs) [40, 41] . Elevated level of HbA 1c is reported to be toxic to the body and has damaging effects on multiple organs. Measuring HbA 1c concentrations in blood is reported to be more convenient than oral glucose tolerance test in the context of glycaemic control and therapeutic benefits [42] . In our present study, we observed a higher HbA1c level in diabetic rats receiving no treatment than in normal rats. Administration of PCTNL for 14 days showed significant lowering effects in diabetic rats.
MDA is an aldehyde formed in biological systems during breakdown of lipid hydroperoxides as well as prostaglandin biosynthesis [43, 44] . Likewise, SOD and GSH are two leading antioxidant machineries that protect cells and their components from oxidative damage by ROS [2] . Increased MDA level and reduced activities of antioxidant machineries indicate oxidative stress conditions. Here, we found a sharp fall in activity of these free radical scavengers in the control diabetic rats. PCTNL 14-days treatment significantly brought back the diminished activities of SOD and GSH. Moreover, we observed a highly elevated level of MDA in the diabetic group with no treatment, while PCTNL-treated groups showed nearly normal MDA levels. These changes may be attributed to the antioxidant property of PCTNL. Increased expression of NF-kB in kidney glomeruli and renal tubules has been reported in diabetic patients with nephropathy [33] . Oxidative stress induced by the chronic hyperglycaemic condition can directly or indirectly activate NF-kB. In DM, prolonged hyperglycaemia increases oxidative stress leading to an increase in formation of glycated products of lipids and proteins [advanced glycated end products (AGE)]. Increased AGE concentrations up-regulate cell surface receptors for it (RAGE) and RAGE when stimulated by AGE; it causes activation of transcription factor NF-kB. In addition, oxygen derivatives released during oxidative stress conditions can directly induce NF-kB activation. Normally, NF-kB rests in the cytosol in association with IjB. On activation, IjB gets dissociated from p50/p65 subunits. The activated NF-kB (i.e. free NF-kB p50/p65 subunits) then translocates into nucleus which results in transcription of many of its downstream genes including pro-inflammatory cytokines such as IL-1b, IL-6 and TNF-a [45, 46] . In our current study, increased NF-kB p50/p65 binding to DNA in kidney tissues of the diabetic control group indicates a higher oxidative stress condition. PCTNL-treated rats showed significantly low levels of renal NF-kB p50/p65 binding suggesting its renal NF-kB inhibitory action. Further, we measured renal concentrations of inflammatory cytokines. Increased levels of pro-inflammatory cytokines and progression of diabetic renovascular complications both have shown to be positively corelated. Inflammatory cytokines such as TNF-a, IL-6 and IL-1b are leading contributors to the development and the progression of diabetic nephropathy [47] . Among these three, pleiotropic TNF-a is reported to have direct cytotoxic effects on renal cells including epithelial, glomerular and mesangial cells. Moreover, TNF-a is involved in NF-kB activation to influence transcription of several genes associated with cell proliferation and survival, pro-inflammatory response and cell adhesion, and inhibition of apoptosis [48] . Likewise, higher expression of IL-6 leads to thickening of glomerular capillaries and tubular atrophy. It can also increase permeability of glomerular capillaries and mesangial cell proliferation [49] . On the other hand, IL-1b is suggested to cause abnormal changes in intraglomerular haemodynamics. Increase in renal IL-1b expression is sensed by several renal cell types and partly associated with mesangial prostaglandin E 2 (PGE2) synthesis and release of phospholipase A2 (PLA2). Besides, the cytokine evokes the expression of intracellular adhesion molecule 1, vascular cell adhesion molecule 1 and E-selectin [50] . Another important role of IL-1b in pathogenesis of DM is induction of inducible nitric oxide synthase (iNOS). This cytokine has the ability to stimulate iNOS expression, which in turn leads to increased levels of NO and the net result is nitrosative stress [51] . Our results showed remarkably elevated levels of these pro-inflammatory cytokines and NO, in kidney tissues of diabetic control rats. In PCTNL-treated rats, we observed significantly low renal tissue concentrations of these inflammatory cytokines and NO. Importantly, rats treated with at a dose of 30 mg/kg b.w. did not show significant results in case of renal IL-1b and IL-6 concentrations. Overall, our results are suggestive of nephroprotective action of PCTNL. At this moment, even though we are unable to describe how PCTNL lowered blood glucose in the treated diabetic rats, the above findings sufficiently provide evidence to prove our hypothesis that PCTNL attenuates hyperglycaemia induced oxidative stress. In addition, it inhibits the development of renal inflammatory micro-environment via attenuation of oxidative stress and AGE induced NF-kB activation. NF-kB inhibition might also be a possible mechanism by which it lowers renal pro-inflammatory cytokines and NO levels ( fig. 5) .
From the histopathological findings, we established that PCTNL treatment effectively ameliorates diabetic glomerulopathy. It restored the glomerular morphology of diabetic kidney to almost normal. Further, it prevented glomerular deposition of sclerotic debris and caused healing of necrotized tubules. These findings further confirm the nephroprotective action of PCTNL in diabetes.
Conclusion
With the support of the above evidences, we conclude that PCTNL is a protective stilbene against diabetic renovascular damage and may find clinical application in the early stage of diabetic nephropathy.
